Home/Pipeline/ATH-1105

ATH-1105

Amyotrophic Lateral Sclerosis (ALS)

Phase 1/2Active

Key Facts

Indication

Amyotrophic Lateral Sclerosis (ALS)

Phase

Phase 1/2

Status

Active

Company

LeonaBio

About LeonaBio

LeonaBio, a rebranded entity from Athira Pharma, is a clinical-stage biotech focused on oncology and neurology. Its strategy pivoted decisively in late 2025 with the in-licensing of the Phase 3 breast cancer candidate lasofoxifene and a financing package of up to $236 million. The company's mission is to advance targeted, small molecule therapeutics for specific, underserved patient populations, leveraging differentiated mechanisms of action to address critical resistance pathways in cancer and neurodegeneration.

View full company profile

Therapeutic Areas

Oncology Neurology

Other Amyotrophic Lateral Sclerosis (ALS) Drugs

Drug	Company	Phase	Status
NPT520-34	Neuropore Therapies	Pre-clinical/Phase 1	Partnered (Biogen), Active
NUZ-001	Neurizon Therapeutics	Phase 2/3 (Platform Trial)	Active
CNM-Au8	Clene	Phase 2/3	Active
Masitinib	AB Science	Phase 3	Active
Undisclosed Program	Zhimeng Biopharma	Clinical	Active
SLS-005	Seelos Therapeutics	Platform Trial	Active (HEALEY ALS Platform Trial – Regimen E)
PMN442	ProMIS Neurosciences	Preclinical	Active
nAV-101	nVector	Pre-clinical	Active
ALTA-808	Alteron Therapeutics	Preclinical	IND-enabling studies launching
GM6	Genervon Biopharmaceuticals	Phase 2	Active
Lou Gehrig’s disease	Genclis	Discovery	Active
Treg-directed therapy for ALS	Iltoo Pharma	Pre-clinical	Active